A recent practice guideline published by the American Psychiatric Association (APA)36 recommended that the FDA-approved drugs disulfiram, naltrexone, and acamprosate be offered to patients with moderate-to-severe AUD. The data reviewed here support the use of naltrexone to reduce the risk of binge drinking and acamprosate to maintain abstinence. However, the use of disulfiram appears justified only when its administration is supervised to ensure adherence. The APA guideline also suggests that gabapentin or topiramate be offered to patients who prefer one of these drugs or who are intolerant of or have not responded to the FDA-approved medications.36
